The latest unsurprising development in 23andMe’s story is the admission, by their new board of directors, that 23andMe now does not have enough cash to continue for the next 12 months. They are now ...
The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...
By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...
A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...
Embattled genetics testing giant 23andMe is thinking of selling itself as it runs out of cash. The company needs ...
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...
It is incumbent not only on people to have the willingness to learn, but also on pharmaceutical and scientific industries to ...
The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) ("23andMe" or the "Company"), a leading human genetics company ...
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...
Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...
The Board of Directors of 23andMe previously formed the Special Committee, which is comprised of independent directors, to review strategic alternatives that may be available to 23andMe. The Special ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback